Research programme: adenovirus-based cancer immunotherapeutics - Targovax

Drug Profile

Research programme: adenovirus-based cancer immunotherapeutics - Targovax

Alternative Names: ONCOS 802; ONCOS 902; ONCOS-402

Latest Information Update: 13 Jul 2015

Price : $50

At a glance

  • Originator Oncos Therapeutics
  • Developer Targovax
  • Class Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 06 Jul 2015 Oncos Therapeutics has been acquired by Targovax
  • 11 Jun 2015 Preclinical trials in Solid tumours in Finland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top